ABSTRACT
NMR spectroscopy has been used for many years to study the effect of one molecule interacting with another, but it was with the inception of the research conducted by Fesik et al. at Abbot Laboratories1 that NMR fragment-based drug discovery (FBDD) was recognised as a widely applicable screening method.
